keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer recurrence

keyword
https://www.readbyqxmd.com/read/29149380/psa-kinetics-following-primary-focal-cryotherapy-hemiablation-in-organ-confined-prostate-cancer-patients
#1
Michael Kongnyuy, Shahidul Islam, Alfred K Mbah, Daniel M Halpern, Glenn T Werneburg, Kaitlin E Kosinski, Connie Chen, David J Habibian, Jeffrey T Schiff, Anthony T Corcoran, Aaron E Katz
PURPOSE: We aim to evaluate prostate-specific antigen (PSA) trends in post-primary focal cryotherapy (PFC) patients. MATERIALS AND METHODS: This was an institutional review board-approved retrospective study of PFC patients from 2010 to 2015. Patients with at least one post-PFC PSA were included in the study. Biochemical recurrence (BCR) was determined using the Phoenix criteria. PSA bounce was also assessed. We analyzed rates of change of PSA over time of post-PFC between BCR and no BCR groups...
November 17, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/29145267/osteoblastic-bone-metastases-from-neuroendocrine-tumor-net-of-unknown-origin-detected-by-18fluorocholine-pet-ct-and-its-comparison-with-68gallium-dotatoc-pet-ct-case-report-and-review-of-the-literature
#2
Alberto Bongiovanni, Federica Recine, Monica Celli, Giulia Marcantognini, Flavia Foca, Chiara Liverani, Valentina Fausti, Alessandro De Vita, Giacomo Miserocchi, Laura Mercatali, Dino Amadori, Toni Ibrahim
RATIONALE: Choline (CH) positron emission tomography (PET)/computed tomography (CT) with fluorine 18 (F) CH is increasingly used not only to evaluate patients with biochemically recurrent prostate cancer but also to assess metastatic lesions that are difficult or impossible to identify using more conventional modalities. Our experience with CH PET/CT has shown that it can also be used for many other malignancies. PRESENTING CONCERNS: A 71-year-old male with a neuroendocrine tumor (NET) of unknown origin showed osteoblastic bone metastases positive to F-CH PET...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29144944/re-impact-of-ga-68-psma-11-pet-on-management-in-patients-with-biochemically-recurrent-prostate-cancer
#3
Samir S Taneja
No abstract text is available yet for this article.
December 2017: Journal of Urology
https://www.readbyqxmd.com/read/29143354/synthesis-and-biological-properties-of-radiohalogenated-%C3%AE-%C3%AE-disubstituted-amino-acids-for-pet-and-spect-imaging-of-amino-acid-transporters-aats
#4
Mark M Goodman, Weiping Yu, Nashwa Jarkas
Fluorine-18 and iodine-123 labeled non-natural alicyclic and methyl branched disubstituted α,α-amino acids are a diverse and useful class of tumor imaging agents suitable for positron emission tomography (PET) and single photon emission computed tomography (SPECT). These tracers target the increased expression of the cell membrane amino acid transporter systems L, ASC and A exhibited by many human tumor cells. The most established clinical use for these radiolabeled amino acids is imaging primary and recurrent gliomas, and primary, recurrent and metastatic prostate cancer...
November 16, 2017: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/29143114/cancer-vaccine-strategies-translation-from-mice-to-human-clinical-trials
#5
REVIEW
Jay A Berzofsky, Masaki Terabe, Jane B Trepel, Ira Pastan, David F Stroncek, John C Morris, Lauren V Wood
We translated two cancer vaccine strategies from mice into human clinical trials. (1) In preclinical studies on TARP, an antigen expressed in most prostate cancers, we mapped epitopes presented by HLA-A*0201, modified them to increase affinity and immunogenicity in HLA transgenic mice, and induced human T cells that killed human cancer cells ("epitope enhancement"). In a clinical trial, HLA-A2(+) prostate cancer patients with PSA biochemical recurrence (Stage D0) were vaccinated with two peptides either in Montanide-ISA51 or on autologous dendritic cells (DCs)...
November 15, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29141559/new-histopathological-genetic-features-to-improve-active-surveillance-selection-for-low-risk-prostate-cancer
#6
Lih-Ming Wong, Kevin Chu, Niall Corcoran, Sam Norden
BACKGROUND: A recent surge in biomarkers to aid management of men with prostate cancer has occurred. Their applications are varied and not all tests are applicable to the active surveillance setting. OBJECTIVE: To review primary evidence on genetic and immunohistochemical biomarkers, and their role on patient selection and risk stratification for men on active surveillance for prostate cancer. EVIDENCE ACQUISITION: A PubMed electronic search using the terms (biomarker or genetic or histopathological) AND ("prostate cancer" AND "active surveillance") was performed from inception to April 2015...
November 13, 2017: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29137956/pattern-of-relapse-and-dose-received-by-the-recurrent-intraprostatic-nodule-in-low-to-intermediate-risk-prostate-cancer-treated-with-single-fraction-19-gy-high-dose-rate-brachytherapy
#7
Lucas C Mendez, Ananth Ravi, Hans Chung, Chia-Lin Tseng, Matt Wronski, Moti Paudel, Merrylee McGuffin, Patrick Cheung, Andrew Loblaw, Gerard Morton
PURPOSE: The purposes of this study were to investigate the pattern of relapse in patients with low- or intermediate-risk prostate cancer treated with 19-Gy high-dose-rate brachytherapy (HDR-BT) and to calculate the dose received by the area of recurrence. METHODS AND MATERIALS: Patients included in this analysis were treated under a Phase II randomized trial that evaluated the role of 19-Gy HDR-BT monotherapy in low- and intermediate-risk prostate cancers. Multiparametric prostate MRI and prostate biopsy were performed in patients with suspicious local recurrence...
November 11, 2017: Brachytherapy
https://www.readbyqxmd.com/read/29137875/contribution-of-11-c-choline-pet-ct-in-prostate-carcinoma-biochemical-relapse-with-serum-psa-level-below-1-ng-ml
#8
F J Gómez-de la Fuente, I Martínez-Rodríguez, M de Arcocha-Torres, R Quirce, J Jiménez-Bonilla, N Martínez-Amador, I Banzo
OBJECTIVE: (11)C-choline PET/CT has demonstrated good results in the restaging of prostate cancer (PCa) with high serum prostate specific antigen (PSA), but its use in patients with low serum PSA is controversial. Our aim was to evaluate the contribution of (11)C-choline PET/CT in patients with PCa, biochemical relapse and PSA <1 ng/ml. MATERIAL AND METHOD: Fifty consecutive patients (mean age: 65.9±5.6 years) with biochemical relapse of PCa and serum PSA <1ng/ml were evaluated retrospectively...
November 11, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29137438/prognostic-value-of-bone-scan-index-as-an-imaging-biomarker-in-metastatic-prostate-cancer-a-meta-analysis
#9
Dongyang Li, Hang Lv, Xuanyu Hao, Yudi Dong, Huixu Dai, Yongsheng Song
Background: The prognostic value of the bone scan index (BSI) in metastatic prostate cancer (mPCa) remained controversial. Therefore, we performed a meta-analysis to determine the predictive value of BSI and survival in patients with mPCa. Materials and Methods: A literature search was performed in PubMed, Embase, Web of Science and Cochrane library databases. Hazard ratios (HRs), concordance indices (C-indices) were extracted to estimate the relationship between BSI and survival in patients with mPCa...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29137428/pten-loss-is-associated-with-prostate-cancer-recurrence-and-alterations-in-tumor-dna-methylation-profiles
#10
Milan S Geybels, Min Fang, Jonathan L Wright, Xiaoyu Qu, Marina Bibikova, Brandy Klotzle, Jian-Bing Fan, Ziding Feng, Elaine A Ostrander, Peter S Nelson, Janet L Stanford
Background: Prostate cancer (PCa) with loss of the tumor suppressor gene PTEN has an unfavorable prognosis. DNA methylation profiles associated with PTEN loss may provide further insights into the mechanisms underlying these more aggressive, clinically relevant tumors. Methods: The cohort included patients with clinically localized PCa. Samples taken from the primary tumor were used to determine PTEN genomic deletions using FISH, and to analyze epigenome-wide DNA methylation profiles...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29137414/salvage-lymph-node-dissection-after-68-ga-psma-or-18-f-fec-pet-ct-for-nodal-recurrence-in-prostate-cancer-patients
#11
Annika Herlemann, Alexander Kretschmer, Alexander Buchner, Alexander Karl, Stefan Tritschler, Lina El-Malazi, Wolfgang P Fendler, Vera Wenter, Harun Ilhan, Peter Bartenstein, Christian G Stief, Christian Gratzke
The management of patients with biochemical recurrence (BCR) after definitive treatment for prostate cancer remains controversial. Our aim was to determine survival rates and complications of salvage lymph node dissection (sLND) in patients with recurrent prostate cancer after radical prostatectomy, while evaluating biochemical response (BR) with two different positron emission tomography/computed tomography (PET/CT) tracers used for preoperative imaging. sLND was performed in 104 patients diagnosed with isolated nodal recurrence on either (18)F-fluoroethylcholine ((18)F-FEC) or (68)Ga-PSMA-HBED-CC ((68)Ga-PSMA) PET/CT...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29137340/prognostic-role-of-tumour-associated-macrophages-and-macrophage-scavenger-receptor-1-in-prostate-cancer-a-systematic-review-and-meta-analysis
#12
Jian Cao, Jun Liu, Ran Xu, Xuan Zhu, Xiaokun Zhao, Bin-Zhi Qian
Recent studies suggested that the tumour associated macrophages may be associated with prostate cancer outcome. A meta-analysis was performed to evaluate the prognostic value of tumor associated macrophages and macrophage scavenger receptor 1, marker for a subset of macrophages, by pooled hazard ratio and 95% confidence intervals from qualified studies following a systemic search. The results indicate that higher infiltration of tumor associated macrophages predicts poor overall survival (HR=1.57, 95%CI: 1...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29134670/altered-mitochondrial-genome-content-signals-worse-pathology-and-prognosis-in-prostate-cancer
#13
Anton M F Kalsbeek, Eva K F Chan, Judith Grogan, Desiree C Petersen, Weerachai Jaratlerdsiri, Ruta Gupta, Ruth J Lyons, Anne-Maree Haynes, Lisa G Horvath, James G Kench, Phillip D Stricker, Vanessa M Hayes
BACKGROUND: Mitochondrial genome (mtDNA) content is depleted in many cancers. In prostate cancer, there is intra-glandular as well as inter-patient mtDNA copy number variation. In this study, we determine if mtDNA content can be used as a predictor for prostate cancer staging and outcomes. METHODS: Fresh prostate cancer biopsies from 115 patients were obtained at time of surgery. All cores underwent pathological review, followed by isolation of cancer and normal tissue...
November 14, 2017: Prostate
https://www.readbyqxmd.com/read/29133278/imaging-for-the-detection-of-locoregional-recurrences-in-biochemical-progression-after-radical-prostatectomy-a-systematic-review
#14
REVIEW
Kristina Sandgren, Philippe Westerlinck, Joakim H Jonsson, Lennart Blomqvist, Camilla Thellenberg Karlsson, Tufve Nyholm, Piet Dirix
CONTEXT: Local and regional recurrence after radical prostatectomy (RP) can be treated using salvage radiotherapy (SRT). If the recurrence can be delineated on diagnostic imaging, this could allow for increasingly individualized SRT. OBJECTIVE: This systematic review aimed at evaluating the evidence regarding the usefulness of positron emission tomography (PET) and magnetic resonance imaging (MRI) in identifying local and regional recurrences, with the aim to further individualize the SRT treatment...
November 10, 2017: European Urology Focus
https://www.readbyqxmd.com/read/29129756/assessment-of-oncological-outcomes-after-radical-prostatectomy-according-to-preoperative-and-postoperative-cancer-of-the-prostate-risk-assessment-scores-results-from-a-large-two-center-experience
#15
Sami-Ramzi Leyh-Bannurah, Paolo Dell'Oglio, Emanuele Zaffuto, Alberto Briganti, Jonas Schiffmann, Raisa S Pompe, Derya Tilki, Hans Heinzer, Markus Graefen, Pierre I Karakiewicz, Lars Budäus
BACKGROUND: Among prostate cancer (PCa) patients undergoing radical prostatectomy (RP) and with virtually identical unfavorable pathological characteristics, those deemed at low risk (LR) preoperatively had better oncological outcomes than those with intermediate (IR) or high risk (HR) preoperatively. OBJECTIVE: To examine if this phenomenon still applies when preoperative Cancer of the Prostate Risk Assessment (CAPRA) scores are compared to postoperative scores (CAPRA-S) in RP patients...
November 9, 2017: European Urology Focus
https://www.readbyqxmd.com/read/29128577/pathological-and-3-tesla-volumetric-mr-predictors-of-biochemical-recurrence-after-robotic-assisted-radical-prostatectomy-correlation-with-whole-mount-histopathology
#16
Nelly Tan, Luyao Shen, Pooria Khoshnoodi, Héctor E Alcalá, Weixia Yu, William Hsu, Robert E Reiter, David Y Lu, Steven S Raman
OBJECTIVE: To identify the clinical and MRI variables predictive of biochemical recurrence (BCR) after robotic assisted radical prostatectomy (RALP) in patients who underwent multi-parametric 3 Tesla prostate MR Imaging. METHODS: An IRB approved, HIPAA compliant, a single arm observational study with 3T mpMRI prior to RALP from December 2009 until March 2016 was performed. Clinical, MRI, pathological information and clinical outcome were compiled. Biochemical recurrence was defined as PSA greater > 0...
November 8, 2017: Journal of Urology
https://www.readbyqxmd.com/read/29127096/retention-of-interstitial-genes-between-tmprss2-and-erg-is-associated-with-low-risk-prostate-cancer
#17
Stephen J Murphy, Farhad Kosari, R Jeffrey Karnes, Aqsa Nasir, Sarah H Johnson, Athanasios G Gaitatzes, James B Smadbeck, Laureano J Rangel, George Vasmatzis, John C Cheville
TMPRSS2-ERG gene fusions occur in over 50% of prostate cancers, but their impact on clinical outcomes is not well understood. Retention of interstitial genes between TMPRSS2 and ERG has been reported to influence tumor progression in an animal model. In this study, we analyzed the status of TMPRSS2-ERG fusion genes and interstitial genes in tumors from a large cohort of men treated surgically for prostate cancer, associating alterations with biochemical progression. Through whole-genome mate pair sequencing, we mapped and classified rearrangements driving ETS family gene fusions in 133 cases of very low-, low-, intermediate-, and high-risk prostate cancer from radical prostatectomy specimens...
November 10, 2017: Cancer Research
https://www.readbyqxmd.com/read/29126844/prospective-outcome-analysis-of-the-safety-and-efficacy-of-partial-and-complete-cryoablation-in-organ-confined-prostate-cancer
#18
A Barqawi, E Huebner, K Krughoff, C I O'Donnell
OBJECTIVES: To determine the rate of complications and change in IPSS and SHIM scores following cryotherapy treatment of low and intermediate risk prostate cancer. Secondary endpoint was change in PSA post-cryotherapy and biopsy-proven recurrence. METHODS: Enrollment occurred from 2007-2015 to assess long-term complications of cryotherapy. A prostate biopsy was performed at one year or in the event of biochemical failure. Subjects were staged and graded by standard 12-14 core TRUS biopsy...
November 7, 2017: Urology
https://www.readbyqxmd.com/read/29126446/detection-level-and-pattern-of-positive-lesions-using-psma-pet-ct-for-staging-prior-to-radiation-therapy
#19
Nina-Sophie Schmidt-Hegemann, Wolfgang Peter Fendler, Alexander Buchner, Christian Stief, Paul Rogowski, Maximilian Niyazi, Chukwuka Eze, Minglun Li, Peter Bartenstein, Claus Belka, Ute Ganswindt
BACKGROUND: To determine the potential role of (68)Ga-PSMA positron emission tomography/computed tomography (PET/CT) in radiotherapy (RT) planning for prostate cancer (PCa). METHODS: One hundred twenty-nine patients (pts) with (68)Ga-PSMA PET/CT were retrospectively analysed. Potentially influencing factors (androgen deprivation therapy, amount of (68)Ga-PSMA-HBED-CC, PSA doubling time ≤/> 10 months, PSA before PET/CT, T-/N-category and Gleason score) were evaluated by logistic regression analysis...
November 10, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/29123407/association-of-pten-expression-with-biochemical-recurrence-in-prostate-cancer-results-based-on-previous-reports
#20
Haijie Xie, Bin Xie, Chunyu Liu, Jun Wang, Yong Xu
Purpose: Among men, prostate cancer (PCa) is one of the most commonly diagnosed cancers and the leading cause of cancer death worldwide. Phosphatase and tension homolog (PTEN) acts as a negative regulator of the phosphatidylinositol 3-kinase (PIK3)/Akt pathway and suppresses tumor progression. Meanwhile, PTEN is frequently deleted in PCa. Identifying the specific molecular markers of biochemical recurrence (BCR) in PCa patients is critical in clinical practice. Our systematic review summarizes the evidence about the PTEN expression and BCR rate in PCa patients...
2017: OncoTargets and Therapy
keyword
keyword
33996
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"